TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02298192
Drug: insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
Study: NCT02878733
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
Study: NCT01393756
Drug: Lenalidomide and R-CHOP
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
Study: NCT00098605
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT01464242
Drug: Meglumine antimonate
Normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime® 20mg/kg/day IM daily for 20 days
Study: NCT01464242
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 400mg orally 3 times a day for 20 days
Study: NCT03230474
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
Study: NCT03230474
Drug: Morphine-Naloxone
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
Study: NCT03011450
Drug: K-877
Normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03011450
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02907320
Drug: placebo CYCLO 3 ® FORT
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00374322
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1500 mg (6 tablets) daily for 12 months
Study: NCT01178086
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab IV
Study: NCT00596440
Drug: Transdermal nicotine patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
Study: NCT03838042
Drug: Nivolumab and Entinostat
Normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
Study: NCT03133975
Drug: Vitamin D3 (Treatment)
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose vitamin D3 in treatment of dyslipedemia
Study: NCT01212770
Drug: Apremilast 20mg
Normalized name: APREMILAST 20MG ORAL TAB
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 20 mg twice daily, orally
Study: NCT01212770
Drug: Apremilast 30mg
Normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 30 mg twice daily, orally
Study: NCT02243943
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02243943
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02483169
Drug: cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100mg bid
Study: NCT02483169
Drug: Probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol 250mg bid
Study: NCT02483169
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg qd
Study: NCT02483169
Drug: placebo of cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: same shape and size of active cilostazol
Study: NCT03839251
Drug: abilify maintena
Normalized name: Abilify Maintena
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aripiprazole 400mg or 300mg, IM, Once a month
Study: NCT01349569
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
Study: NCT00001768
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04139070
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electroporation in combination with systemically administered bleomycin
Study: NCT01387880
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan.
Study: NCT01387880
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.66 mg per day up to 7½ mg per day
Study: NCT00838110
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TID for week 1 followed by 20 mg TID through Week 26
Study: NCT00838110
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TID for week 1 followed by 20 mg TID through Week 12
Study: NCT01003899
Drug: afatinib (BIBW 2992)
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: afatinib (BIBW 2992) po QD
Study: NCT01262651
Drug: Nabiximols
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01443481
Drug: Dovitinib
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
Study: NCT03588533
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks
Study: NCT03588533
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
Study: NCT05630274
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT05630274
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02552004
Drug: IV fluorescein administration
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Fluorescein (fluorescent contrast agent) administration
Study: NCT01786512
Drug: Omecamtiv Mecarbil Matrix F1 Formulation
Normalized name: Matrix
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release tablets for oral administration
Study: NCT01786512
Drug: Omecamtiv Mecarbil Matrix F2 Formulation
Normalized name: Matrix
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release tablets for oral administration
Study: NCT01786512
Drug: Omecamtiv Mecarbil Swellable Core Technology F2
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release tablets for oral administration
Study: NCT00003466
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02204826
Drug: Korean Red Ginseng (KRG)
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.
Study: NCT02260648
Drug: Evacetrapib
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02260648
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT02260648
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03935165
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~- Indocyanine Green is administered Intravenously
Study: NCT04237740
Drug: relenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
Study: NCT00790101
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002933
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
Study: NCT03162224
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.
Study: NCT00760929
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg oral daily
Study: NCT00324870
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00324870
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02634411
Drug: 15 days of effective antibiotic treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days.
Study: NCT02194426
Drug: MP0250
Normalized name: VEGF/HGF-targeting darpin MP0250
DrugBank: MP-0250 (DB17218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
Study: NCT02003001
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02206503
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02206503
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01352338
Drug: Lenalidomide, endoxan, prednisone
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose-finding
Study: NCT01352338
Drug: lenalidomide, endoxan, prednisone
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT05354050
Drug: DARE-BV1
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Clindamycin 100 MG
Study: NCT03204279
Drug: Netupitant
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
Study: NCT03204279
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
Study: NCT03204279
Drug: Netupitant
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
Study: NCT02277106
Drug: SAGE-547
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00790101
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00211250
Drug: Valproic Acid and Depakote ER
Normalized name: valproate Extended Release Oral Tablet [Depakote]
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02293902
Drug: Sarilumab SAR153191 (REGN88)
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT01935336
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib 45mg taken by mouth each day at the same time with or without food
Study: NCT02541708
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
Study: NCT00574080
Drug: Interim/Maintenance Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
Study: NCT00574080
Drug: Induction/Consolidation Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg Days 1-4
Study: NCT00574080
Drug: Induction/Consolidation Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 by continuous infusion Days 1-4
Study: NCT00574080
Drug: Induction/Consolidation Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m2 by continuous infusion Days 1-4
Study: NCT00574080
Drug: Induction Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg Days 6 and 13
Study: NCT00574080
Drug: Transplant 1 Dexamethasone
Normalized name: dexamethasone 1 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
Study: NCT00574080
Drug: Transplant 1 Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 by continuous infusion Days -3 and -2
Study: NCT00574080
Drug: Transplant 1 Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 by continuous infusion Days -3 and -2
Study: NCT00574080
Drug: Transplant 1 Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80 mg/m2 by continuous infusion Days -3 and -2
Study: NCT00417170
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 300 mg tablets taken orally once daily
Study: NCT00574080
Drug: Transplant 1 Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 Days -2 and -1
Study: NCT00574080
Drug: Transplant 1 and 2 Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg Day +6
Study: NCT00574080
Drug: Transplant 2 Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/m2 Day -5
Study: NCT00574080
Drug: Transplant 2 Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 Days -5, -4, -3, -2
Study: NCT00574080
Drug: Transplant 2 Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 Days -5, -4, -3, -2
Study: NCT00417170
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg capsule taken orally once daily
Study: NCT00417170
Drug: Placebo Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Aliskiren taken orally once daily.
Study: NCT00417170
Drug: Placebo Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Amlodipine taken orally once daily
Study: NCT00574080
Drug: Transplant 2 Melphalan
Normalized name: melphalan 2 MG
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m2 Day -1
Study: NCT00574080
Drug: Transplant 2 Dexamethasone
Normalized name: dexamethasone 2 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
Study: NCT00574080
Drug: Transplant 1 and 2 Bortezomib
Normalized name: bortezomib 1 MG
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/m2 Days -4, -1, +3, +7
Study: NCT00574080
Drug: Transplant 1 and 2 Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg Days -4 to +5
Study: NCT00000392
Drug: Peptide T
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01806376
Drug: Subutinib Maleate capsules
Normalized name: chlorpheniramine maleate Oral Capsule
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation will be dependent on any dose limiting toxicities
Study: NCT04015414
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
Study: NCT04015414
Drug: Cytisine
Normalized name: Cytisine
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
Study: NCT00805545
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
Study: NCT02288065
Drug: sterile talc pleurodesis
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medical thoracoscopy and talc pleurodesis. No specific device is studied.
Study: NCT01830296
Drug: Remifentanil+morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine, Remifentanil+Morphine
Study: NCT00150059
Drug: Pimecrolimus Cream 1%
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02157506
Drug: CXL-1427
Normalized name: CXL-1020
DrugBank: CXL-1020 (DB15326)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01182337
Drug: Intradiscal rhGDF-5
Normalized name: CHYMOPAPAIN 2nKatU/ML INTRADISCAL
DrugBank: Chymopapain (DB06752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
Study: NCT01182337
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
Study: NCT03658993
Drug: Rifaximin 550 MG
Normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Rifaximin 550 mg TID for 4 weeks.